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to metformin observed in the different Hb genotypes presented here
as well as the lack of response in nonSCD patients in the previous
report.5
Here we report the first in vivo evidence of using metformin in SCD
patients. We demonstrate HbF increase was minimal in nonHb SS/Sβ0
patients, consistent with the results in previous nonSCD patients.5 Some
HbF induction was observed in Hb SS/Sβ0 genotype, and combination of
HU with metformin might have additional benefits. Importantly, we did
not find evidence that metformin increases anemia or lactic acidosis in
SCD patients. Our report is limited by the sample size and variability in
the patient baseline characteristics. The compliance to metformin is diffi-
cult to assess due to the retrospective design, which may also contribute
to some of the inter-individual variation in the HbF response. Our find-
ings require substantiation in prospective clinical trials to evaluate the
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The iron chelator, deferasirox, is generally effective and well tolerated,
but issues around ease of use and palatability of dispersible tablets
(DTs) may limit adherence, and by extension efficacy, in some
patients. The ECLIPSE trial (NCT02125877) demonstrated that defer-
asirox film-coated tablets (FCTs) and DT formulations had similar
safety profiles during 6 months of treatment, though fewer patients
treated with FCT experienced severe gastrointestinal-related adverse
events and patient-reported outcomes were more favorable with FCT
than with DT.1
Absolute and relative serum ferritin changes from baseline in each
treatment arm were evaluated monthly during ECLIPSE. While
patients experienced similar exposure to active deferasirox with either
DT or FCT, a greater reduction in serum ferritin levels from baseline
to end of treatment was observed with FCT, with a geometric mean
change of −431 compared with −153 ng/mL with DT.
In the absence of reported efficacy data beyond 6 months for the
FCT in the clinical trial setting, this mathematical modeling analysis
investigated whether the observed difference in serum ferritin levels
between the 2 arms at month 6 of ECLIPSE would have translated
into a sustained difference in treatment effect if the study had contin-
ued through 12 months.
This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited and is
not used for commercial purposes.
© 2018 The Authors. American Journal of Hematology published by Wiley Peri-
odicals, Inc.
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The ECLIPSE study design is described in detail elsewhere.1
Briefly, ECLIPSE was a randomized, open-label, multicenter, Phase II
study in which male or female patients aged ≥10 years with
transfusion-dependent thalassemia or International Prognostic Scor-
ing System lower-risk myelodysplastic syndromes (MDS) received
deferasirox DT (starting dose: 20 mg/kg/d) or FCT (starting dose:
14 mg/kg/d) for 24 weeks. Improved bioavailability of the FCT formu-
lation means that equivalent deferasirox doses are 30% lower for the
FCT than the DT formulation.2
Initial exploratory graphical analyses were conducted to under-
stand the distribution of serum ferritin and of key covariates at base-
line including weight and age.
Two candidate models, using the 12-month data from the
controlled registration study ICL670A108 (NCT00061763),3 were
evaluated to describe changes from baseline in serum ferritin with
deferasirox; both use log transformed serum ferritin measurement:
(1) simple exponential model (random intercept and slope model
of log[serum ferritin]), where treatment effect is on lambda.
SF tð Þ¼ SF_0* exp − lambda*t <¼> log SF tð Þð Þ¼ log SF_0ð Þ− lambda*t:
(2) Verhulst model that has a saturation effect after an initial
exponential decrease, where treatment effect is on gamma.4
SF tð Þ¼ SF_0* gamma* exp lambda*t = gamma−1+ exp lambda*t  :
The 1-year prospective, multicenter, and Phase II ICL670A108
study evaluated deferasirox efficacy in transfusion-dependent patients
with MDS (n = 47), β-thalassemia (n = 85), Diamond-Blackfan anemia
(n = 30), or other rare anemias (n = 22). Patients in this study were
deferasirox-naïve, unlike most ECLIPSE patients who had received prior
deferasirox. After discarding the first 3-month serum ferritin data from
ICL670A108, patients were considered nondeferasirox-naive, and the
subsequent serum ferritin data from months 4 to 10 were used to
fit the models, and those from months 11 to 12 served to test model
prediction accuracy.
The final model was selected by comparing model perfor-
mance based on prediction accuracy and using out-of-sample
information criteria.5 The population and individual level predictive
properties of the final model on the out-of-sample data, including
coverage, bias, and root mean square error (RMSE), were also
evaluated.
In ECLIPSE, 86 patients were randomized to receive DT, and
87 patients to receive FCT. Mean (SD) patient age was 34.9 (19.3)
years, and 90% had previously received iron chelation therapy. Over
24 weeks, the mean (SD) actual daily deferasirox dose was 27.5 (7.7)
mg/kg/day in the DT group, and 20.8 (5.4) mg/kg/day in the FCT
group, indicating similar deferasirox exposure. At baseline, geometric
mean serum ferritin was 2381 and 2721 ng/mL in the DT and FCT
arms, respectively.
Model diagnostics showed that the difference in the informa-
tion metric between the 2 models was greater than 100 points in
favor of the Verhulst model, suggesting the latter has superior
leave-one-out predictive performance and, therefore, was suitable
for predicting new data with acceptable accuracy. However, some
degree of overfitting was observed with the ICL670A108 data
(high shrinkage on slope and residual error term; inflated 50% cov-
erage). Additionally, the out-of-sample performance metrics
showed that the individual level model resulted in lower RMSE
and allowed for less bias compared with the population level
model, suggesting that serum ferritin value forecasting for the
ECLIPSE patient population was best achieved using individual
level model predictions.
The final model predictions yielded a close approximation of the
ECLIPSE data; the predicted geometric mean serum ferritin values
during the first 6 treatment months were similar to the actual serum
ferritin values observed during the trial (Figure 1). Importantly, the
model predicted that geometric mean serum ferritin would continue
to decrease over the subsequent 6 months with both deferasirox DT
and FCT, reaching 2162 ng/mL (90% CI 2029-2304) with deferasirox
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FIGURE 1 Serum ferritin with model prediction for completers of the ECLIPSE trial. Circle and triangle data points represent actual geometric
mean serum ferritin value observed during the ECLIPSE trial. Solid lines represent model prediction for serum ferritin values with error bars
showing 90% CIs of the predicted geometric mean. Abbreviations: DT, dispersible tablet; FCT, film-coated tablet
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12 months of treatment. The predicted relative serum ferritin reduc-
tion at 12 months was 10% (90% CI 2-17) with deferasirox DT, and
19% (90% CI 12-25) with deferasirox FCT. It is important to note that
mean actual deferasirox dose remained stable throughout the
6-month study with both DT (27.1-28.2 mg/kg/day) and FCT
(20.1-21.6 mg/kg/day).
According to the predicted results from the proposed model,
and with a similar exposure to deferasirox, patients treated with
FCT would have had a greater reduction in serum ferritin at
12 months than patients treated with DT. Although it cannot be
excluded that other factors might have influenced the trajectories of
this model, such as the higher baseline serum ferritin values in the
FCT group, this greater serum ferritin reduction with deferasirox
FCT could be attributed to better treatment adherence. Previous
analyses have indicated that improved patient-reported outcomes,
especially increased adherence, are significant mediators of the
association between treatment with deferasirox DT vs FCT, and the
reduction from baseline in serum ferritin achieved over 6 months of
treatment.6 Further exploration of long-term efficacy outcomes and
their associated factors is needed to confirm improved efficacy with
deferasirox FCT.
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Triplet-based lenalidomide plus dexamethasone combinations have
become a new standard of care for early relapsed refractory multiple
myeloma (RRMM),1 improving the outcome of MM over the past
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